10x Genomics Stock Buy Hold or Sell Recommendation
| TXG Stock | USD 28.95 0.21 0.72% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding 10X Genomics is 'Sell'. Macroaxis provides 10X Genomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TXG positions. The advice algorithm takes into account all of 10X Genomics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting 10X Genomics' buy or sell advice are summarized below:
Real Value 35.79 | Target Price 60.33 | Hype Value 28.62 | Market Value 28.95 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell 10X Genomics given historical horizon and risk tolerance towards 10X Genomics. When Macroaxis issues a 'buy' or 'sell' recommendation for 10X Genomics, the advice is generated through an automated system that utilizes algorithms and statistical models.
10X |
Execute 10X Genomics Buy or Sell Advice
The 10X recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on 10X Genomics. Macroaxis does not own or have any residual interests in 10X Genomics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute 10X Genomics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
10X Genomics Trading Alerts and Improvement Suggestions
| 10X Genomics generated a negative expected return over the last 90 days | |
| The company reported the last year's revenue of 618.73 M. Reported Net Loss for the year was (255.1 M) with profit before taxes, overhead, and interest of 396.02 M. | |
| 10X Genomics has about 499.73 M in cash with (15.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: 10x Genomics Shares Gap Down Following Analyst Downgrade - MarketBeat |
10X Genomics Returns Distribution Density
The distribution of 10X Genomics' historical returns is an attempt to chart the uncertainty of 10X Genomics' future price movements. The chart of the probability distribution of 10X Genomics daily returns describes the distribution of returns around its average expected value. We use 10X Genomics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of 10X Genomics returns is essential to provide solid investment advice for 10X Genomics.
| Mean Return | -0.61 | Value At Risk | -5.32 | Potential Upside | 4.58 | Standard Deviation | 2.90 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of 10X Genomics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
10X Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 10X Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 10X Genomics backward and forwards among themselves. 10X Genomics' institutional investor refers to the entity that pools money to purchase 10X Genomics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sumitomo Mitsui Trust Holdings Inc | 2023-12-31 | 2.3 M | Venrock Management Vi Llc | 2023-12-31 | 2.1 M | Geode Capital Management, Llc | 2023-12-31 | 1.6 M | State Street Corporation | 2023-12-31 | 1.6 M | Rtw Investments, Llc | 2023-12-31 | 1.5 M | Generation Investment Management Llp | 2023-12-31 | 1.5 M | Jpmorgan Chase & Co | 2023-12-31 | 1.5 M | Bp Wealth Management, Llc | 2023-12-31 | 1.4 M | Point72 Asset Management, L.p. | 2023-09-30 | 1.3 M | Fmr Inc | 2023-12-31 | 12.8 M | Vanguard Group Inc | 2023-12-31 | 9 M |
10X Genomics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (6.7M) | (14.6M) | (30.1M) | (21.2M) | 7.9M | 8.3M | |
| Investments | (42.8M) | (38.4M) | (106.7M) | (350.9M) | 87.2M | 91.6M | |
| Change In Cash | 406.4M | 212.2M | (92.6M) | (368.7M) | 136.9M | 143.8M | |
| Free Cash Flow | (8.1M) | (256.3M) | (122.7M) | (165.3M) | (64.7M) | (68.0M) | |
| Depreciation | 7.1M | 19.0M | 28.3M | 33.0M | 43.6M | 21.9M | |
| Other Non Cash Items | 101K | 306.0M | 79K | 2.0M | 274.9M | 288.7M | |
| Capital Expenditures | 42.8M | 38.4M | 101.3M | 131.7M | 49.5M | 58.8M | |
| Net Income | (31.3M) | (542.7M) | (58.2M) | (166M) | (255.1M) | (267.9M) | |
| End Period Cash Flow | 476.5M | 688.6M | 596.1M | 227.4M | 359.3M | 387.5M | |
| Change To Netincome | 13.9M | 356.2M | 96.0M | 137.9M | 158.6M | 111.7M |
10X Genomics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to 10X Genomics or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that 10X Genomics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a 10X stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.77 | |
β | Beta against NYSE Composite | 2.67 | |
σ | Overall volatility | 2.85 | |
Ir | Information ratio | -0.23 |
10X Genomics Volatility Alert
10X Genomics exhibits very low volatility with skewness of 0.12 and kurtosis of -0.37. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure 10X Genomics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact 10X Genomics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.10X Genomics Fundamentals Vs Peers
Comparing 10X Genomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze 10X Genomics' direct or indirect competition across all of the common fundamentals between 10X Genomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as 10X Genomics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of 10X Genomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing 10X Genomics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare 10X Genomics to competition |
| Fundamentals | 10X Genomics | Peer Average |
| Return On Equity | -0.33 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Profit Margin | (0.41) % | (1.27) % |
| Operating Margin | (0.16) % | (5.51) % |
| Current Valuation | 3.18 B | 16.62 B |
| Shares Outstanding | 105.11 M | 571.82 M |
| Shares Owned By Insiders | 2.38 % | 10.09 % |
| Shares Owned By Institutions | 92.41 % | 39.21 % |
| Number Of Shares Shorted | 8.52 M | 4.71 M |
| Price To Book | 5.56 X | 9.51 X |
| Price To Sales | 6.65 X | 11.42 X |
| Revenue | 618.73 M | 9.43 B |
| Gross Profit | 396.02 M | 27.38 B |
| EBITDA | (158.25 M) | 3.9 B |
| Net Income | (255.1 M) | 570.98 M |
| Cash And Equivalents | 499.73 M | 2.7 B |
| Cash Per Share | 4.39 X | 5.01 X |
| Total Debt | 95.37 M | 5.32 B |
| Debt To Equity | 0.13 % | 48.70 % |
| Current Ratio | 5.65 X | 2.16 X |
| Book Value Per Share | 6.22 X | 1.93 K |
| Cash Flow From Operations | (15.2 M) | 971.22 M |
| Short Ratio | 6.32 X | 4.00 X |
| Earnings Per Share | (2.18) X | 3.12 X |
| Price To Earnings To Growth | 0.13 X | 4.89 X |
| Target Price | 55.5 | |
| Number Of Employees | 1.26 K | 18.84 K |
| Beta | 1.89 | -0.15 |
| Market Capitalization | 3.47 B | 19.03 B |
| Total Asset | 965.14 M | 29.47 B |
| Retained Earnings | (1.28 B) | 9.33 B |
| Working Capital | 468.86 M | 1.48 B |
| Net Asset | 965.14 M |
Note: Disposition of 4660 shares by Serge Saxonov of 10X Genomics at 43.9959 subject to Rule 16b-3 [view details]
10X Genomics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as 10X . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About 10X Genomics Buy or Sell Advice
When is the right time to buy or sell 10X Genomics? Buying financial instruments such as 10X Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 82.0M | 95.2M | 95.4M | 63.7M | Total Assets | 1.0B | 1.0B | 965.1M | 746.1M |
Use Investing Ideas to Build Portfolios
In addition to having 10X Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Iron Thematic Idea Now
Iron
Companies involved in production of steel and iron. The Iron theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
| View All Next | Launch |
Check out 10X Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is 10X Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 5.281 | Quarterly Revenue Growth 0.178 | Return On Assets (0.12) | Return On Equity (0.33) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.